A5101587859- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Renal Diseases and Glomerulopathies
- Polyomavirus and related diseases
- Transplantation: Methods and Outcomes
- Parvovirus B19 Infection Studies
- Blood groups and transfusion
- Pregnancy and Medication Impact
- Organ Donation and Transplantation
- Cytomegalovirus and herpesvirus research
- Dialysis and Renal Disease Management
- Neurological Complications and Syndromes
- Pharmacological Effects and Toxicity Studies
- Metabolism and Genetic Disorders
- Full-Duplex Wireless Communications
- Immunodeficiency and Autoimmune Disorders
- Hepatitis C virus research
- Organ and Tissue Transplantation Research
The University of Kansas Health System
2017
Baylor College of Medicine
2015
Methodist Hospital
2015
Methodist Hospital
2010-2014
Houston Methodist
2011-2014
Methodist Hospital
2012-2013
Background Renal transplant recipients with de novo DSA (dDSA) experience higher rates of rejection and worse graft survival than dDSA-free recipients. This study presents a single-center review dDSA monitoring in large, multi-ethnic cohort renal Methods The authors performed nested case-control adult kidney kidney-pancreas from July 2007 through 2011. Cases were defined as dDSA-positive whereas controls all DSA-negative determined at 1, 3, 6, 9, 12 months posttransplant, every 6 thereafter....
Abstract Background In renal transplantation, BK virus infection can result in significant graft nephropathy and loss. While reduction immunosuppression ( IS ) is considered standard therapy, adjunct agents may be warranted. Data are suggestive of a possible role cidofovir for the management . This study aims to describe course viremia BKV large cohort transplant patients receiving cidofovir. Methods We evaluated kidney kidney‐pancreas recipients who received combined with reduced high‐level...
This study reviewed the outcomes of a screening protocol for BK viremia to determine if early diagnosis, followed by immunosuppression minimization, would prevent progression nephropathy and graft loss.This review included 369 renal transplant recipients tested virus at serial time points after transplantation. Management minimization plus cidofovir treatment nephropathy.Recipients received tacrolimus-based immunosuppression, with 8% prednisone-free 6% who desensitization. With mean...
Abstract Background The natural history of de novo donor‐specific antibodies ( dn DSA ) after lung transplantation is not well‐described. We sought to determine the incidence and risk factors associated with compare outcomes between recipients transient (or isolated) vs persistent transplantation. Methods A single‐center review all transplants from 1/2009‐7/2013. s were tested eight times in first year every 4 months thereafter. Outcomes examined included acute rejection graft failure....
Preemptive transplantation results in excellent patient and graft survival yet most transplant candidates are referred for after initiation of dialysis. The goal this study was to determine barriers preemptive renal transplantation.A nonvalidated questionnaire administered prospective kidney recipients factors that hindered or favored referral before the dialysis.One hundred ninety-seven subjects a primary completed questionnaire. Ninety-one (46%) had been informed referral, 80 (41%) were...
Background . Rituximab is becoming increasingly utilized in renal transplant recipients; however, its association with infections remains unclear. Methods We reviewed the incidence of viral and fungal kidney recipients treated () or without rituximab (RTX) addition to standard immunosuppression. Results Infections occurred 134 (30%) patients, a greater proportion RTX versus no patients (47% 28%; ). Viral 44% 27% respectively (). This was largely driven by frequency BK viremia...
Background: Prospective monitoring of de novo donor specific antibodies (dnDSA) after renal transplant has shown that dnDSA are predictive poor outcomes. The immunomodulatory effects intravenous immune globulin (IVIG) may be beneficial for pre-emptive treatment recipients without acute rejection (AR). Herein, we present preliminary data with and stable function treated IVIG compared to matched controls. Methods: We prospectively monitored all kidney from 7/2007-7/2012. Recipients 2 or more...
Background: Most studies have focused on single time point detection of de novo donor specific antibodies (dnDSA) and adverse outcomes after renal transplant. Longitudinal sensitized dialysis patients reported that some spontaneously clear antibodies, but the pattern impact antibody clearance is unknown. We sought to determine rate spontaneous dnDSA transplant describe associated with versus persistence in without prior rejection. Methods: prospectively monitored 828 kidney transplants for...
Background: Protocol biopsies have been advocated in monitoring kidney transplant recipients, but it is unclear whether these should be performed all recipients or special high risk groups. Additionally, the timing for biopsy this population uncertain. We sought to review our experience with early (1-month) protocol determine if informs patient management. Methods: reviewed 368 renal from 1/2012-10/2013. 19% (71) were risk, defined as either PRA > 75%, pre-transplant anti-HLA donor specific...
Background: The pattern of clearance or persistence de novo donor specific anti-HLA antibodies (dnDSA) is unclear in lung transplant recipients. purpose our study to identify the incidence dnDSA and its a population prospectively monitored recipients predictive factors for clearance. Methods: We reviewed 325 first-time, lung-only from 1/2009-11/2012 who all had at least 1 year follow-up. Of these, we excluded 53 patients DSA prior (6), within 14 days < 2 tests (16), desensitization (22)...
Background: We sought to determine if conversion from tacrolimus/mycophenolate mofetil (MMF) an mTOR inhibitor and low-dose tacrolimus (mTOR) after kidney-pancreas transplantation would reduce the risks of acute rejection BK viremia. Methods: A single center review renal-pancreas transplants 12/2009 12/2013. All recipients received induction immunosuppression with thymoglobulin. The cohort was converted at one month post-transplant tacrolimus/MMF either sirolimus or everolimus (target trough...
Antibody-mediated rejection (AMR) after renal transplantation is frequently resistant to conventional anti-rejection therapy and often results in graft dysfunction (Gdys); however, risk factors for Gdys following AMR remain poorly defined. The purpose of this study was identify predictors Gdys, defined as loss or GFR reduction by ≥50%, at 1 year post-AMR treatment. Kidney transplant recipients treated biopsy-proven (n=49) were reviewed. Factors approaching significance (p<0.2) the univariate...
1Department Of Pharmacy, The Methodist Hospital, Houston/Texas/UNITED STATES OF AMERICA, 2The Houston/TX/UNITED 3The Houston/UNITED 4Cardiology, AMERICA
Management of renal transplant recipients with a negative CDC-AHG cross-match and pre-transplant donor-specific antibody (DSA) is controversial. We sought to compare outcomes sensitized living donor (LD) without DSA. Methods: A single center retrospective review all performed between 1/08 12/10. Pre-transplant desensitization for DSA was not utilized. Immunosuppression consisted thymoglobulin induction, followed by tacrolimus, MMF, prednisone. assessed at one, 3, 6, 9, 12, every 6 months...